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Background and PurposezzMultifocal seeding of the leptomeninges by malignant cells, 
which is usually referred to as leptomeningeal carcinomatous metastasis, produces substantial 
morbidity and mortality. The diagnosis of leptomeningeal metastasis is usually established by 
cerebrospinal fluid (CSF) investigation, including cytology, cell counts, protein, glucose, and a 
tumor marker such as carcinoembryonic antigen (CEA). This study examined the diagnostic 
value of CEA in the CSF.
MethodszzWe measured the CSF CEA level in 32 patients with leptomeningeal metastasis. The 
control group consisted of 19 cancer patients without leptomeningeal metastasis. CEA was mea-
sured by the chemiluminescent emission method.
ResultszzThe CEA level was significantly higher in patients with leptomeningeal metastasis 
than in the control group (p<0.005). The level of CSF protein was higher and that of CSF glu-
cose was lower in patients with leptomeningeal metastasis than in the control group (p<0.005).
ConclusionszzThe CSF CEA level is useful for diagnosing leptomeningeal carcinomatous me-
tastasis. The CSF levels of protein and glucose are also useful in the diagnosis.
  J Clin Neurol 2010;6:33-37
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Introduction
The average human life span is becoming longer due to ad-
vances in medical science, and the incidence rate of cancer is 
increasing. The multifocal spreading of malignant tumor cells 
along the meninges, which is called leptomeningeal metasta-
sis,
1,2 occurs in 5% of all patients diagnosed with cancer. Re-
gardless of the kind of primary cancer, leptomeningeal me-
tastasis results in serious morbidity and mortality.
1,3,4
The diagnostic tools for leptomeningeal metastasis include 
clinical symptoms, neurologic abnormal findings, neurologic 
imaging, and cerebrospinal fluid (CSF) tests. A CSF cytology 
test can be used to confirm leptomeningeal metastasis in can-
cers. The level of carcinoembryonic antigen (CEA), increased 
intracranial pressure, cell numbers, and amount of protein 
are also helpful for the diagnosis.
1,5
CEA is a β-1 glycoprotein with a high molecular weight 
(180 kDa) that is produced in adenocarcinomas such as gas-
trointestinal cancer, breast cancer, lung cancer, ovarian can-
cer, and pancreatic cancer.
6-8 Approximately half (50-60%) 
of this protein is composed of hydrocarbons like sialic acid, 
mannose, galactose, acetyl-N-glucosamine, and fructose. 
The other 40% or so is composed of polypeptides. Small amo-
unts of CEA exist in normal digestive organs, and it is pres-
ent in various bodily fluids such as urine, intestinal secre-
tions, pleural fluid, peritoneal fluid, and CSF.
9-11 However, 
CEA in serum cannot easily pass through the blood-brain 
barrier, which makes it a good marker for carcinomatous in-
filtrations in leptomeninges.
12-14 
Few studies have investigated whether tests for CEA in CSF 
are useful for diagnosing leptomeningeal metastasis. This study 
compared CSF CEA levels between cancer patients without 
leptomeningeal metastasis and cancer patients confirmed as 
having leptomeningeal metastasis by cytology tests. The aim Diagnostic Value of CSF Carcinoembryonic Antigen
34  J Clin Neurol 2010;6:33-37
of this comparison was to determine whether an elevated 
level of CEA is diagnostic of leptomeningeal metastasis.
Methods
 
Study groups
Cancer patients with leptomeningeal metastasis were includ-
ed in this study, with cancer patients without leptomeningeal 
metastasis being chosen as controls. Patients with parenchy-
mal metastasis to the brain or spinal cord were excluded. None 
of the patients in the two study groups had medical or neuro-
logic diseases other than cancer. 
 
Method
Clinical records and CSF tests
The patients provided informed consent to participate in the 
study. For unconscious patients, the informed consent was 
obtained from their legal guardians. We performed neurolog-
ical examinations and reviewed medical records. The metas-
tasis group was reviewed for sex, age, previously diagnosed 
primary cancer site, and metastasis. CSF tests were used to 
detect malignant cells and to measure the levels of protein, 
glucose, and CEA.
Measurement of carcinoembryonic antigen levels in CSF
CSF samples (3 mL) were collected for the tests. When the te-
sts could not be carried out immediately, samples were frozen 
at -70℃ and then thawed at room temperature when required. 
The CEA measurement was based on chemiluminescent 
emissions according to the noncompetitive principle (E170 
kit, Modular Analytics, Roche Diagnostic, Mannheim, Ger-
many), and the results were calculated by spectrophotometry 
at 492 nm.
 
Statistical analysis
Obtained values were compared using the t-test with the 
SPSS statistical analysis program (Version 14.0; SPSS Inc, 
Chicago, IL, USA), and mean±standard deviation values 
were determined. The mean age and sex were determined in 
the metastasis and control groups. CEA, protein and glucose 
levels were compared using the t-test. Primary cancer was 
compared between the metastasis and control groups using 
cross analysis. Statistical significance was set at p<0.05.
 
Results
 
Clinical characteristics
Patients in the metastasis group were aged between 34 and 78 
years (55.28±10.10 years). Those in the control group were 
aged between 32 and 88 years (60.94±14.41 years). The age 
and sex distributions did not differ significantly between the 
two groups (Table 1). 
There were two people aged 30-39 years, seven aged 40-49 
years, fifteen aged 50-59 years, four aged 60-69 years, and 
four aged 70-79 years in the metastatic group. There were 
two people aged 30-39 years, seven aged 40-49 years, five 
aged 60-69 years, four aged 70-79 years, and one aged 80-89 
years in the control group. In the metastasis group, stomach 
cancer was most common, followed by lung cancer, breast 
cancer, esophageal cancer, and cholangiocarcinoma. Stom-
ach cancer was also the most common in the control group, 
followed by lung cancer, breast cancer, colon cancer, and cho-
langiocarcinoma (Table 2). Cross analysis revealed that the 
composition of primary cancer did not differ significantly 
between the two groups (p=0.218).
Table 1. Clinical characteristics
Metastasis* (n=32) Control
† (n=19) p
Age (years) 55.28±10.10 60.94±14.41 0.106
Sex (male/female) 19/13 14/5 0.301
Data are mean±SD values.
*Cancer patients with leptomeningeal carcinomatous metas-
tasis, †Cancer patients without leptomeningeal carcinomatous 
metastasis. 
Table 2. Comparison of primary cancer site between patients with 
and without leptomeningeal metastasis 
Primary cancer site
No. (%)
Metastasis (n=32) Control (n=19)
Stomach 12 (37.5) 7 (36.84)
Lung 12 (37.5) 5 (26.31)
Breast 03 (9.37) 3 (15.78)
Common bile duct 03 (9.37) 1 (5.26)0
Esophagus 02 (6.25) 0 (00.00)
Colon 00 (0.00)  3 (15.78)
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Fig. 1. Comparison of cerebrospinal fluid (CSF) carcinoembryon-
ic antigen (CEA) level between cancer patients with and without 
leptomeningeal carcinomatous metastasis. The CSF CEA level 
was significantly higher in patients with leptomeningeal metasta-
sis. Data are mean and SD values. *p=0.002.
*Kang SJ et al.
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Comparison of carcinoembryonic antigen levels
The CEA level was significantly higher in the metastasis 
group (98.06±59.43 ng/mL) than in the control group (1.53 
±0.38 ng/mL) (Fig. 1). The ratio of serum and CSF CEA lev-
els was about 1:1 in the metastasis group (Fig. 2).
The serum CEA level was higher than 5 ng/mL in 11 pa-
tients in the metastasis group, but only 1 (5.2%) patient in the 
control group had a CSF CEA level of higher than 5 ng/mL 
(Fig. 3). The ratio of the CSF CEA level (5.16 ng/mL) to the 
serum CEA level (290.5 ng/mL) wa s nearly 1 : 60.
For a CSF CEA cutoff level of 5 ng/mL, 26 patients in the 
metastasis group were positive for CSF CEA, whereas only 
1 patient was positive in the control group. Therefore, the 
sensitivity and specificity of CSF CEA were 81.25% and 
94.73%, respectively (Table 3).
Comparison of CSF protein and glucose levels
The CSF glucose level was lower in the metastasis group 
(48.41±32.00 mg/dL) than in the control group (71.53±27.24 
mg/dL). Of the 32 patients, 17 (53.1%) had glucose levels eq-
ual to or lower than 40 mg/dL (Fig. 4).
The CSF protein level was significantly higher in the me-
tastasis group (129±104 mg/dL) than in the control group 
(41.66±14.28 mg/dL). Of the 32 patients, 24 (71.8%) had pro-
tein levels equal to or higher than 50 mg/dL (Fig. 5).
Discussion
Many biochemical markers for the early diagnosis of cancer 
Fig. 2. Relation between CSF and serum CEA levels in the metas-
tasis group. The CSF-to-serum ratio is about 1:1. CEA: carcinoem-
bryonic antigen.
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Table 3. Sensitivity and specificity of carcinoembryonic antigen 
(CAE) level in cerebrospinal fluid
Cytology
Positive Negative
CEA Positive 26 01
Negative 06 18
Sensitivity=81.3%, specificity=94.7%. 
CEA: carcinoembryonic antigen.
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Fig. 4. Comparison of CSF glucose level between patients with 
and without leptomeningeal metastasis. The CSF glucose level 
was significantly lower in patients with leptomeningeal metasta-
sis. Data are mean and SD values. *p=0.011.
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Fig. 5. Comparison of CSF protein level between patients with 
and without leptomeningeal metastasis. The CSF protein was 
significantly higher in patients with leptomeningeal metastasis. 
Data are mean and SD values. *p=0.002. 
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Fig. 3. Relation between CSF and serum CEA levels in the con-
trol group. The CEA level exceeded 5 ng/mL in only 1 of the 19 pa-
tients, and the CSF-to-serum CEA ratio was nearly 1 : 60. This sug-
gests that CSF CEA comes from serum CEA passing through the 
blood-brain barrier. CEA: carcinoembryonic antigen.Diagnostic Value of CSF Carcinoembryonic Antigen
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have been investigated. However, the low sensitivity and 
specificity of serum and CSF levels of biochemical markers 
have limited their usefulness. Cancer markers are molecules 
produced and released directly by cancer cells in amounts 
that exceed those for noncancerous tissues, and so they have 
a high specificity.
12-15 Among these cancer markers, CEA is 
the most well-known cancer-related antigen that can be found 
in bodily fluids, and its utility in screening for cancer based 
on its concentration has been investigated in many studies.
7,9
Serum CEA can be used as a secondary tool in screening 
for groups with a high risk of tumor occurrence, and in situa-
tions when the existence of a tumor cannot be readily con-
firmed. It is also useful during follow-up after cancer treat-
ment, for evaluating treatment effects, and for testing for 
remnant cancer or cancer recurrence. However, it has a low 
sensitivity in such applications, and it has also been found to 
be nonspecifically increased in benign diseases and that 
many factors contribute to its serum concentration, which re-
duces its usefulness.
16,17
There are two hypotheses for why CEA is detected in 
CSF,
12-15,18,19: 1) CEA in CSF is produced by metastatic tis-
sues and 2) serum CEA passes through the blood-brain barri-
er. The former hypothesis is more likely since stroke patients 
with elevated serum CEA do not show elevated CSF CEA 
levels,
20 and the serum CEA level must rise sufficiently to 
produce a serum-to-CSF ratio of 60 : 1 in order to pass 
through the blood-brain barrier.
12,13,21 Therefore, when the se-
rum-to-CSF ratio is less than 60:1, an increase in CSF CEA 
level has a relatively high specificity for leptomeningeal me-
tastasis.
22 Smoking can also increase the serum CEA level, 
although not by enough to cause a false-positive result, and 
this is also true for obesity, age, and sex.
23,24 There is little 
possibility of the CEA level measured in CSF tests being in-
fluenced by factors other than tumor metastasis. Therefore, a 
significant increase in its level can be attributed to the pres-
ence of leptomeningeal metastasis. 
CSF cytology tests in leptomeningeal metastasis showed a 
positivity rate of 54% in the first tests, which increased to 
85% after three tests.
25-28 In some patients with leptomenin-
geal metastasis, as subsequently confirmed by autopsy, the 
CSF CEA level was elevated without malignant cells being 
found in repeated cytology tests.
20 This is because cancer 
cells normally are in one-cell units or form small loose colo-
nies. CSF CEA tests of leptomeningeal metastasis patients in 
previous studies found a low sensitivity of 31% but a high 
specificity of 90%.
20 However, the sensitivity of CEA in our 
study was higher than that in previous studies. We attribute 
this difference to our metastasis group comprising patients 
who were positive in a cytology test. Even though the CSF 
CEA test has a low sensitivity, it will be helpful when per-
forming a CSF cytology test.
This study found that the CEA levels were significantly 
higher in patients diagnosed with leptomeningeal metastasis 
(as confirmed by finding cancer cells in CSF cytology tests) 
than in patients without leptomeningeal metastasis. There-
fore, CSF CEA tests can be used not only to evaluate the ef-
fect of treatment and recurrence of cancer,
12,29 but also to di-
agnose leptomeningeal metastasis. In the metastasis group, 
24 patients (71.8%) had a CSF protein level higher than 50 
mg/dL and 17 patients (53.1%) had a CSF glucose level low-
er than 40 mg/dL. These results are similar to those from 
previous studies.
30
We conclude that when findings suspicious of leptomenin-
geal metastasis such as headaches, vomiting, neurologic dis-
orders, and decreased consciousness are accompanied in pa-
tients diagnosed for cancer, testing CEA concentrations in 
CSF will have an important diagnostic value. In conclusion,   
elevated serum CEA is influenced by various factors, and so 
is of limited usefulness in deciding whether tumor metastasis 
is present. However, an increased CSF CEA appears to be di-
agnostic of cancer cell metastasis. An increase in protein lev-
el or a decrease in glucose level is also useful for the diagno-
sis of leptomeningeal metastasis.
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